Bacterial vectors for active immunotherapy reach clinical and industrial stages

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 10, 2012, Pages 1454-1458

  Gouëllec, Audrey Le ^a   Chauchet, Xavier ^a   Polack, Benoit ^a   Buffat, Laurent ^b   Toussaint, Bertrand ^a  

^a UNIV GRENOBLE ALPES   (France)

^b APCure SAS   (France)

Author keywords

Antigen delivery; Attenuation; Bacteria; Immunotherapy; Listeria; Pseudomonas

Indexed keywords

EID: 84868266538     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21429     Document Type: Note

References (33)

1. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787- 96; PMID:20948547; http://dx.doi.org/10.1038/ nri2868.
2. AUTHOR: Please provide reference 2.
3. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306; PMID:15803149; http://dx.doi. org/10.1038/nri1592.
4. Blander JM, Sander LE. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat Rev Immunol 2012; 12:215- 25; PMID:22362354; http://dx.doi.org/10.1038/ nri3167.
5. Chamekh M. Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: potential application in vaccine and therapeutical developments. Immunopharmacol Immunotoxicol 2010; 32:1-4; PMID:19778176; http://dx.doi. org/10.3109/ 08923970902817890.
6. Epaulard O, Derouazi M, Margerit C, Marlu R, Filopon D, Polack B, et al. Optimization of a type III secretion system-based Pseudomonas aeruginosa live vector for antigen delivery. Clin Vaccine Immunol 2008; 15:308-13; PMID:18094108; http://dx.doi. org/10.1128/CVI.00278-07.
7. Epaulard O, Toussaint B, Quenee L, Derouazi M, Bosco N, Villiers C, et al. Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol Ther 2006; 14:656-61; PMID:17010670; http://dx.doi. org/10.1016/j.ymthe.2006.06.011.
8. Hegazy WA, Xu X, Metelitsa L, Hensel M. Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens. Infect Immun 2012; 80:1193- 202; PMID:22252866; http://dx.doi.org/10.1128/ IAI.06056-11.
9. Evans DT, Chen LM, Gillis J, Lin KC, Harty B, Mazzara GP, et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 2003; 77:2400-9; PMID:12551977; http://dx.doi. org/10.1128/JVI.77.4.2400-2409.2003.
10. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res 1995; 55:4776- 9; PMID:7585503.
11. Paterson Y, Johnson RS. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004; 3(Suppl):S119-34; PMID:15285711; http://dx.doi.org/10.1586/14760584.3.4.S119.
12. Guirnalda P, Wood L, Paterson Y. Listeria monocytogenes and its products as agents for cancer immunotherapy. Adv Immunol 2012; 113:81-118; PMID:22244580; http://dx.doi.org/10.1016/B978- 0-12-394590-7.00004-X.
13. Shahabi V, Maciag PC, Rivera S, Wallecha A. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs 2010; 1:235-43; PMID:21327055; http://dx.doi. org/10.4161/bbug.1.4.11243.
14. Sleator RD, Hill C. 'Bioengineered Bugs' - a pathobiotechnology approach to probiotic research and applications. Med Hypotheses 2008; 70:167-9; PMID:17452084; http://dx.doi.org/10.1016/j. mehy.2007.03.008.
15. Spreng S, Dietrich G, Weidinger G. Rational design of Salmonella-based vaccination strategies. Methods 2006; 38:133-43; PMID:16414270; http://dx.doi. org/10.1016/j.ymeth.2005.09.012.
16. Stocker BA. Auxotrophic Salmonella typhi as live vaccine. Vaccine 1988; 6:141-5; PMID:3291451; http://dx.doi.org/10.1016/S0264-410X(88)80017-3.
17. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004; 101:13832- 7; PMID:15365184; http://dx.doi.org/10. 1073/ pnas.0406035101.
18. VanCott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, et al. Regulation of host immune responses by modification of Salmonella virulence genes. Nat Med 1998; 4:1247-52; PMID:9809547; http://dx.doi.org/10.1038/3227.
19. Sauer JD, Pereyre S, Archer KA, Burke TP, Hanson B, Lauer P, et al. Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity. Proc Natl Acad Sci U S A 2011; 108:12419- 24; PMID:21746921; http://dx.doi.org/10.1073/ pnas.1019041108.
20. Wang Y, Gouëllec AL, Chaker H, Asrih H, Polack B, Toussaint B. Optimization of antitumor immunotherapy mediated by type III secretion systembased live attenuated bacterial vectors. J Immunother 2012; 35:223-34; PMID:22421940; http://dx.doi. org/10.1097/CJI.0b013e31824747e5.
21. Dubensky TW Jr., Skoble J, Lauer P, Brockstedt DG. Killed but metabolically active vaccines. Curr Opin Biotechnol 2012; PMID:22608846; http://dx.doi. org/10.1016/j.copbio.2012.04.005.
22. Irsch J, Lin L. Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™. Transfus Med Hemother 2011; 38:19-31; PMID:21779203; http:// dx.doi.org/10.1159/000323937.
23. Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005; 11:853-60; PMID:16041382; http:// dx.doi.org/10.1038/nm1276.
24. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001; 167:6471-9; PMID:11714814.
25. Lauer P, Chow MY, Loessner MJ, Portnoy DA, Calendar R. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol 2002; 184:4177- 86; PMID:12107135; http://dx.doi.org/10.1128/ JB.184.15.4177-4186.2002.
26. Verch T, Pan ZK, Paterson Y. Listeria monocytogenes- based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun 2004; 72:6418- 25; PMID:15501772; http://dx.doi.org/10.1128/ IAI.72.11.6418-6425.2004.
27. Spreng S, Viret JF. Plasmid maintenance systems suitable for GMO-based bacterial vaccines. Vaccine 2005; 23:2060-5; PMID:15755571; http://dx.doi. org/10.1016/j.vaccine.2005.01.009.
28. Curtiss R 3rd, Galan JE, Nakayama K, Kelly SM. Stabilization of recombinant avirulent vaccine strains in vivo. Res Microbiol 1990; 141:797-805; PMID:1966252; http://dx.doi.org/10.1016/0923- 2508(90)90113-5.
29. Polack B, Vergnaud S, Paclet MH, Lamotte D, Toussaint B, Morel F. Protein delivery by Pseudomonas type III secretion system: Ex vivo complementation of p67(phox)-deficient chronic granulomatous disease. Biochem Biophys Res Commun 2000; 275:854-8; PMID:10973811; http://dx.doi. org/10.1006/bbrc.2000.3399.
30. Sheehan VM, Sleator RD, Fitzgerald GF, Hill C. Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl Environ Microbiol 2006; 72:2170-7; PMID:16517668; http://dx.doi. org/10.1128/AEM.72.3.2170-2177.2006.
31. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27:3975-83; PMID:19389451; http:// dx.doi.org/10.1016/j.vaccine.2009.04.041.
32. Singh R, Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin 2011; 7:497- 505; PMID:21422819; http://dx.doi.org/10.4161/ hv.7.5.15132.
33. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010; 10:785- 94; PMID:20944664; http://dx.doi.org/10.1038/ nrc2934